Hutchison China Meditech Ltd (LON:HCM) Rating Reaffirmed
This Morning, 21 December, Hutchison China Meditech Ltd (LON:HCM)’s Buy rating was kept steady by Analysts at Beaufort Securities in a note.
From a total of 1 analysts covering Hutchison China Meditech Ltd (LON:HCM) stock, 0 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that NaN of the ratings are positive. Hutchison China Meditech Ltd was the topic of 4 analyst reports since July 28, 2015 according to the firm StockzIntelligence Inc. Beaufort Securities maintained shares on December 21 with “Buy” rating.
Approximately 200 shares of stock traded hands. Hutchison China MediTech Limited (LON:HCM) has risen 40.90% since May 22, 2015 and is uptrending. It has outperformed by 46.70% the S&P500.
Hutchison China MediTech Limited is a China-based, globally-focused healthcare group. The company has a market cap of 1.52 billion GBP. The Firm researches, develops, makes and sells pharmaceuticals and health-related consumer products. It has 2310.67 P/E ratio. The Company’s Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.